GDGraciel Diamante

Graciel Diamante

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Graciel Diamante has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mapping the hepatic regulatory landscape of estradiol in gonadectomized obese female and male mice at single-nucleus resolution

    by Yutian Zhao, Ruirui Lan, In Sook Ahn, Sophia Yu, Guanglin Zhang, Graciel Diamante, Bridget Litts, Ariel Thorson, Kelsey P. Schaefers, Xia Yang, et al.

    Background: Obesity is a prevalent, systemic metabolic disease affecting not only various adipose depots but also the liver, where lipid accumulation results in metabolic dysfunction-associated fatty liver disease, dyslipidemia, and insulin resistance. While estradiol (E2) has been known to be hepatoprotective for glucose and lipid metabolism in females, whether E2’s effects on individual liver cell types are shared between sexes or are sex-specific with obesity remains poorly defined. Methods: We performed single-nucleus RNA sequencing on liver tissue of E2-treated obese, gonadectomized male (XY) and female (XX) mice with diet-induced obesity to evaluate the sex-concordant and discordant effects of chronic E2 treatment. Differential gene expression, pathway analysis, intracellular and intercellular regulatory network modeling, and human metabolic disease/trait association analysis were conducted. Results: E2-induced transcriptional effects among hepatocyte subtypes were largely sex-concordant in both males and females, along with sex-specific E2 changes. In pericentral hepatocytes, E2 concordantly reduced the expression of genes involved in insulin resistance, FOXO signaling, and lipid biosynthesis; in periportal hepatocytes, E2 treatment enhanced cholesterol efflux genes and suppressed oxidative stress response genes. XY-specific effects of E2 included additional suppression of lipid and energy metabolic pathways in pericentral hepatocytes and oxidative phosphorylation in periportal hepatocytes, while in XX mice E2 showed unique regulation of glucose and lipid utilization programs. Network analysis revealed that E2-responsive genes in hepatocyte subtypes in both sexes showed enriched transcription factors associated with estrogen receptor signaling and lipid sensing and metabolism, alongside sex-specific regulators. Intercellular signaling affected by E2 showed more changes in XY mice than in XX mice across hepatocyte subtypes. Lastly, while E2-responsive genes in hepatocyte subtypes of both sexes were enriched for human genetic signals associated with lipid profiles and coronary artery disease, we also identified sex-specific associations, such as the link of E2-downregulated genes in XY hepatocytes to body mass index in men. Conclusions: Our findings revealed that chronic E2 administration remodels gene regulatory programs in individual liver cell types through both shared and sex-specific mechanisms, highlighting the importance of considering sex chromosome-dependent E2 responses when developing therapeutic strategies for obesity and associated hepatic metabolic dysfunction.

  • Open Access

    Disparate Metabolomic Responses to Fructose Consumption between Different Mouse Strains and the Role of Gut Microbiota

    by In-Sook Ahn, Justin Yoon, Graciel Diamante, Peter Cohn, Cholsoon Jang, Xia Yang

    High fructose consumption has been linked to metabolic syndrome, yet the fructose-induced phenotypes, gene expression, and gut microbiota alterations are distinct between mouse strains. In this study, we aim to investigate how fructose consumption shapes the metabolomic profiles of mice with different genetic background and microbiome. We used fructose-sensitive DBA/2J (DBA) and fructose-resistant C57BL/6J (B6) mice given 8% fructose or regular water for 12 weeks. Plasma and fecal metabolites were profiled using a liquid chromatography-tandem mass spectrometry based global metabolomic approach. We found that the baseline metabolomic profiles were different between DBA and B6 mice, particularly plasma metabolites involved in lipid metabolism and fecal metabolites related to dipeptide/amino acid metabolism. In response to fructose, DBA mice showed a distinct decrease of plasma branched chain fatty acids with concordantly increased branched chain amino acids, which were correlated with adiposity; B6 mice had significantly increased plasma cholesterol and total bile acids, accompanied by decreased fecal levels of farnesoid X receptor antagonist tauro-β-muricholate, which were correlated with fructose-responsive bacteria Dehalobacterium, Magibacteriaceae, and/or Akkermansia. Our results demonstrate that baseline metabolomic profiles differ and respond differentially to fructose between mice with different genetic background and gut microbiota, which may play a role in individualized risks to fructose-induced metabolic syndrome.


  • Open Access

    PharmOmics: A Species- and Tissue-specific Drug Signature Database and Online Tool for Drug Repurposing

    by Yen-Wei Chen, Graciel Diamante, Jessica Ding, Thien Xuan Nghiem, Jessica Yang, Sung-Min Ha, Peter Cohn, Douglas Arneson, Montgomery Blencowe, Jennifer Garcia, et al.

    Drug development has been hampered by a high failure rate in clinical trials due to efficacy or safety issues not predicted by preclinical studies in model systems. A key contributor is our incomplete understanding of drug functions across organ systems and species. Therefore, elucidating species- and tissue-specific actions of drugs can provide systems level insights into therapeutic efficacy, potential adverse effects, and interspecies differences that are necessary for more effective translational medicine. Here, we present a comprehensive drug knowledgebase and analytical tool, PharmOmics, comprised of genomic footprints of drugs in individual tissues from human, mouse, and rat transcriptome data from GEO, ArrayExpress, TG-GATEs, and DrugMatrix. Using multi-species and multi-tissue gene expression signatures as molecular indicators of drug functions, we developed gene network-based approaches for drug repositioning. We demonstrate the potential of PharmOmics to predict drugs for new disease indications and validated two predicted drugs for non-alcoholic fatty liver disease in mice. We also examined the potential of PharmOmics to identify drugs related to hepatoxicity and nephrotoxicity. By combining tissue- and species-specific in vivo drug signatures with biological networks, PharmOmics serves as a complementary tool to support drug characterization.


  • Open Access

    Prenatal Bisphenol A Exposure in Mice Induces Multi-tissue Multi-omics Disruptions Linking to Cardiometabolic Disorders

    by Le Shu, Qingying Meng, Brandon Tsai, Graciel Diamante, Yen-Wei Chen, Andrew Mikhail, Helen Luk, Beate Ritz, Patrick Allard, Xia Yang

    The health impacts of endocrine disrupting chemicals (EDCs) remain debated and their tissue and molecular targets are poorly understood. Here, we leveraged systems biology approaches to assess the target tissues, molecular pathways, and gene regulatory networks associated with prenatal exposure to the model EDC Bisphenol A (BPA). Prenatal BPA exposure led to scores of transcriptomic and methylomic alterations in the adipose, hypothalamus, and liver tissues in mouse offspring, with cross-tissue perturbations in lipid metabolism as well as tissue-specific alterations in histone subunits, glucose metabolism and extracellular matrix. Network modeling prioritized main molecular targets of BPA, including Pparg, Hnf4a, Esr1, Srebf1 , and Fasn . Lastly, integrative analyses identified the association of BPA molecular signatures with cardiometabolic phenotypes in mouse and human. Our multi-tissue, multi-omics investigation provides strong evidence that BPA perturbs diverse molecular networks in central and peripheral tissues, and offers insights into the molecular targets that link BPA to human cardiometabolic disorders.

  • SAW1 is required for SDSA double-strand break repair in S. cerevisiae

    by Graciel Diamante, Claire Phan, Angie S. Celis, Jonas Krueger, Eric P. Kelson, Paula L. Fischhaber